Dispositional optimism and therapeutic expectations in early-phase oncology trials

Lynn Jansen, Daruka Mahadevan, Paul S. Appelbaum, William M P Klein, Neil D. Weinstein, Motomi (Tomi) Mori, Racky Daffé, Daniel P. Sulmasy

Research output: Contribution to journalArticle

21 Scopus citations

Abstract

BACKGROUND: Prior research has identified unrealistic optimism as a bias that might impair informed consent among patient-subjects in early-phase oncology trials. However, optimism is not a unitary construct; it also can be defined as a general disposition, or what is called dispositional optimism. The authors assessed whether dispositional optimism would be related to high expectations for personal therapeutic benefit reported by patient-subjects in these trials but not to the therapeutic misconception. The authors also assessed how dispositional optimism related to unrealistic optimism. METHODS: Patient-subjects completed questionnaires designed to measure expectations for therapeutic benefit, dispositional optimism, unrealistic optimism, and the therapeutic misconception. RESULTS: Dispositional optimism was found to be significantly associated with higher expectations for personal therapeutic benefit (Spearman rank correlation coefficient [r], 0.333; P

Original languageEnglish (US)
JournalCancer
DOIs
StateAccepted/In press - 2016

Keywords

  • Cancer research
  • Dispositional optimism
  • Informed consent
  • Therapeutic misconception
  • Therapeutic optimism

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Dispositional optimism and therapeutic expectations in early-phase oncology trials'. Together they form a unique fingerprint.

  • Cite this

    Jansen, L., Mahadevan, D., Appelbaum, P. S., Klein, W. M. P., Weinstein, N. D., Mori, M. T., Daffé, R., & Sulmasy, D. P. (Accepted/In press). Dispositional optimism and therapeutic expectations in early-phase oncology trials. Cancer. https://doi.org/10.1002/cncr.29908